F14 for Postoperative Pain After Knee Replacement
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests if injecting a long-lasting painkiller called celecoxib into the knee can help reduce pain for patients having knee replacement surgery. The medication works by blocking chemicals that cause pain and swelling. Celecoxib has been shown to be effective in reducing pain and improving function in patients with knee osteoarthritis.
Will I have to stop taking my current medications?
Yes, you will need to stop taking certain medications. You must discontinue nonsteroidal anti-inflammatory drugs (NSAIDs), medical or recreational marijuana, cannabidiol (CBD), pregabalin, gabapentin, and opioid analgesics at least 7 to 10 days before the surgery and for a specified period after the surgery.
Who Is on the Research Team?
Matthew Shive, PhD
Principal Investigator
Arthritis Innovation Corporation
Are You a Good Fit for This Trial?
Adults aged 45-80, with a BMI ≤ 40 kg/m2, scheduled for unilateral total knee replacement surgery can join. They must have stable health as confirmed by tests and no recent injections or major surgeries in the affected knee. Women of childbearing age need a negative pregnancy test and agree to birth control measures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intra-articular dose of F14 (625 mg sustained release celecoxib) concurrent with multimodal analgesia during total knee replacement surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- F14
Find a Clinic Near You
Who Is Running the Clinical Trial?
Arthritis Innovation Corporation
Lead Sponsor
Allucent
Collaborator